Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models

15Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

When we look at the rapid growth of scientific databases on the Internet in the past decade, we tend to take the accessibility and provenance of the data for granted. As we see a future of increased database integration, the licensing of the data may be a hurdle that hampers progress and usability. We have formulated four rules for licensing data for open drug discovery, which we propose as a starting point for consideration by databases and for their ultimate adoption. This work could also be extended to the computational models derived from such data. We suggest that scientists in the future will need to consider data licensing before they embark upon re-using such content in databases they construct themselves. © 2012 Williams et al.

Cite

CITATION STYLE

APA

Williams, A. J., Wilbanks, J., & Ekins, S. (2012). Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models. PLoS Computational Biology, 8(9). https://doi.org/10.1371/journal.pcbi.1002706

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free